Humana (NYSE:HUM) Trading Down 4.5% – Should You Sell?

Humana Inc. (NYSE:HUMGet Free Report) shares were down 4.5% during mid-day trading on Monday . The company traded as low as $259.96 and last traded at $262.09. Approximately 466,929 shares traded hands during trading, a decline of 68% from the average daily volume of 1,443,565 shares. The stock had previously closed at $274.33.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HUM. Barclays upped their target price on Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 22nd. TD Cowen raised their price objective on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Piper Sandler lifted their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and increased their price target for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company decreased their price objective on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Nineteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $296.84.

Check Out Our Latest Analysis on HUM

Humana Price Performance

The stock’s 50-day moving average price is $273.00 and its 200-day moving average price is $295.72. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $30.91 billion, a price-to-earnings ratio of 22.74, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56.

Humana (NYSE:HUMGet Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities research analysts anticipate that Humana Inc. will post 16.11 earnings per share for the current year.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Creative Financial Designs Inc. ADV increased its holdings in shares of Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 61 shares in the last quarter. FPC Investment Advisory Inc. acquired a new stake in shares of Humana during the fourth quarter worth $27,000. Centricity Wealth Management LLC acquired a new stake in shares of Humana in the 4th quarter valued at about $30,000. Ashton Thomas Securities LLC acquired a new stake in shares of Humana in the 3rd quarter valued at about $31,000. Finally, Your Advocates Ltd. LLP lifted its holdings in shares of Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Company Profile

(Get Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Articles

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.